Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Current evidence indicates that statins increase the risk of new onset diabetes mellitus (NOD) and also deteriorate the glycemic control in patients with known diabetes mellitus (DM) after high-dose statin therapy.
Aims: The aim of this review was to explore the effect of atorvastatin in causing NOD or deteriorating glycemic control in patients with DM.
Methods: Two independent reviewers conducted the literature search, through PubMed database searching for articles published in English until April 2015, and only primary studies were included.
Results: Of the 919 articles identified in our original search, 33 met the criteria for this review encompassing 1,951,113 participants. Twenty articles examined dysregulation of DM due to atorvastatin. Half of them showed that there was no significant change in glycemic control in patients treated with atorvastatin. Other studies showed that fasting plasma glucose and HbA1c levels were increased by atorvastatin. Thirteen articles examined if atorvastatin causes NOD. The majority of these articles showed that patients who used atorvastatin had a higher dose-dependent risk of developing NOD.
Conclusion: This systematic review suggests that there is an association between atorvastatin treatment and NOD. Moreover, it showed that atorvastatin in high dose causes worsening of the glycemic control in patients with DM.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6217757 | PMC |
| http://dx.doi.org/10.1155/2018/8380192 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
An early prediction of postprandial glycemia evolution using the MD001 algorithm: a muticentre prospective trial.
Cell Mol Biol (Noisy-le-grand)
September 2025
M-DT1, Roquefort-les Pins, France.
To date, the closed-loop system represents the best commercialized management of type 1 diabetes. However, mealtimes still require carbohydrate estimation and are often associated with postprandial hyperglycemia which may contribute to poor metabolic control and long -term complications. A multicentre, prospective, non-interventional clinical trial was designed to determine the effectiveness of a novel algorithm to predict changes in blood glucose levels two hours after a usual meal.
View Article and Find Full Text PDFRisk factors for coronary in-stent restenosis in Moroccan patients: a retrospective case-control study.
Cell Mol Biol (Noisy-le-grand)
September 2025
Medical School, Laboratory of Genetics and Molecular Pathology, University Hassan II, Casablanca, Morocco.
In-stent restenosis remains a significant challenge in interventional cardiology despite technological advancements. This retrospective case-control study conducted at the University Hospital Center Ibn Rochd in Casablanca (2020-2023) examined risk factors associated with coronary in-stent restenosis in 68 patients equally distributed between restenosis and no-restenosis groups. Diabetes emerged as a powerful predictor of restenosis (RR=4.
View Article and Find Full Text PDFEffectiveness and Safety of Insulin Glargine 300 U/ml in High-Risk Subgroups (Renal Impairment and Older Age ≥ 70 years) of Insulin-Naïve People with Type 2 Diabetes: A Post hoc Analysis of Real-World ATOS Study.
Diabetes Ther
September 2025
Department of Diabetes and Endocrinology, Guy's and St Thomas' NHS Trust, London, UK.
Introduction: This post hoc analysis of an A Toujeo Observational Study (ATOS) aims to evaluate the real-world effectiveness and safety of insulin glargine 300 U/ml (Gla-300) in high-risk subgroups of insulin-naïve people with type 2 diabetes (PwT2D) from multiple geographical regions (Asia, the Middle East, North Africa, Latin America, and Eastern Europe).
Methods: In these post hoc analyses of ATOS, a real-world, 12-month, prospective study included 4422 insulin-naïve adults (age ≥ 18 years) with type 2 diabetes (T2D) uncontrolled (HbA > 7% and ≤ 11%) on one or more oral antidiabetic drugs (OADs) who initiated Gla-300 treatment as per routine practice. Primary and secondary endpoints were studied according to renal impairment (RI) status (without or with) and age group ( View Article and Find Full Text PDF
L. as a Potential Alternative Therapy to Improve the Management of Diabetes: An Overview on Phytochemical Insights, Mechanisms, and Therapeutic Applications.
Int J Vitam Nutr Res
August 2025
Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Dhaka, 1000 Dhaka, Bangladesh.
Diabetes mellitus (DM) is a chronic metabolic disorder characterized by persistent hyperglycemia and associated with severe complications, including cardiovascular diseases, neuropathy, nephropathy, and retinopathy. Although synthetic antidiabetic drugs are available, the side effects and limited long-term effectiveness of these medications highlight the urgent need for safer, more potent alternative therapies. L.
View Article and Find Full Text PDFLow-protein Calorie-restriction Mitigates Diabetic Mice Kidney Injury via the Gut-Kidney Axis.
Int J Vitam Nutr Res
August 2025
Department of Endocrinology, Affiliated Hospital of Integrated Chinese and Western Medicine, Nanjing University of Chinese Medicine, 210028 Nanjing, Jiangsu, China.
Background: Dietary interventions have exhibited promise in restoring microbial balance in chronic kidney disease. A low-protein calorie-restricted diet can reduce kidney injury in diabetic rodents. However, whether the renoprotective effects of this dietary intervention in murine diabetic kidney disease models are linked to gut microbiota modulation remains to be determined.
View Article and Find Full Text PDF